Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-28T17:45:37.331Z Has data issue: false hasContentIssue false

Predictive Value of P53-Positive Cells for Esophageal Cancer Micrometastasis

Published online by Cambridge University Press:  02 July 2020

C. Wei
Affiliation:
Cardiothoracic Molecular Research, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, 21201
Y. Mao
Affiliation:
Cardiothoracic Molecular Research, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, 21201
M. Krasna
Affiliation:
Cardiothoracic Molecular Research, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, 21201
Get access

Extract

Esophageal cancer is the fastest growing malignancy of any tumor in the United States with an increased incidence of adenocarcinoma across all socioeconomic boundaries. The stage and the residual tumor classification are the most important prognostic factors. However, patients with similar stage of disease show a marked difference in survival. Therefore, there are needs to identify new molecular prognostic markers that may help to better assess the survival probability.

The recently introduced genetic diagnosis of cancer micrometastasis is quite attractive because of its high detection sensitivity. Not infrequently, however, there are marked discrepancies between genetic and conventional histologic diagnoses, especially concerning lymph nodes from carcinoma patients. Alterations in the p53 tumor suppressor gene are the most frequent genetic changes found in breast and lung cancer. The p53 gene functions as a negative regulator of cell growth. Alterations in the gene lead to loss of its usual negative growth regulation and more rapid cell proliferation.

Type
Pathology
Copyright
Copyright © Microscopy Society of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References:

1.Elledge, R. M., et al. Breast Cancer Res Treat (1993) 27, 95102.CrossRefGoogle Scholar
2.Dobashi, K., et al, J Thorac Cardiovasc Surg (1997) 114, 339346.CrossRefGoogle Scholar
3.Yamamoto, N., et al. Cancer (1997) 80, 13931398.3.0.CO;2-G>CrossRefGoogle ScholarPubMed
4. This research was supported in part by grants from the NIH (HL03174 & HL61299, C Wei), and University of Maryland School of Medicine.Google Scholar